Contact Us

TOURISM NEWS

CCTV+: Yuhang Journey ǀ Follow Olivier to Explore Ancient Liangzhu and Savor Jingshan Tea

Dec 10, 2024

BEIJING,Dec. 8,2024-- "Hello everyone,this isLaolu…" Olivier,a Frenchman who has lived in China for 30 years,speaks fluent Chinese and is a natural in front of the camera. When asked why he

Blokees' Figures from Multiple IPs Amaze Fans at 2024 Singapore Comic Con

Dec 10, 2024

SHANGHAI,Dec. 8,2024-- During the two-day 2024 Singapore Comic Con (December 7–8),Blokees unveiled its new Sesame Street collection for the first time globally and showcased an impressive array of fi

Fenjiu a cultural messenger with aroma flowing globally

Dec 10, 2024

FUZHOU,China,Dec. 7,2024-- A report from Huanqiu.com: Fenjiu,as a Chinese liquor with thousands of years of brewing techniques and profound cultural heritage,has been actively connecting with the inte

Maropost unveils AI-powered email marketing features that boost conversions for commerce brands

Dec 10, 2024

TORONTO,Dec. 6,2024-- Maropost,the connected commerce platform revolutionizing mid-market merchant operations,today announced two groundbreaking AI-driven features for its Marketing Cloud product.

The revival of Notre-Dame witnesses the value of cultural exchange and mutual learning: Global Times editorial

Dec 10, 2024

BEIJING,Dec. 9,2024-- The restored Notre-Dame de Paris cathedral reopened on Sunday,following a grand ceremony held the day before. In his speech at the ceremony,French President Emmanuel Macron expre

2024 ASH Oral Presentation----Abbisko presents promising preliminary phase 2 study results of pimicotinib in the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting

Dec 10, 2024

SHANGHAI,Dec. 9,2024-- December 8,2024,Abbisko Therapeutics (HKEX: 02256) announced the presentation of preliminary Phase 2 study results for pimicotinib (ABSK021) in patients with chronic Graft-versu

1 ... 186 187 188 189 190 191 192 ... 347